{
    "clinical_study": {
        "@rank": "45270", 
        "acronym": "RETRO-HF", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "30 mg dose of JVS-100", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "45 mg dose of JVS-100", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "A phase I/II study to evaluate the safety and efficacy of JVS-100 administered by retrograde\n      delivery to cohorts of adults with Ischemic Heart Failure."
        }, 
        "brief_title": "Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Heart Failure", 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Ischemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "72 subjects with ischemic cardiomyopathy. The Phase I portion (n=12 subjects) will be open\n      label. In the first cohort, six subjects will receive a single dose of 30 mg of JVS-100 with\n      a minimum of 3 days between each enrollment. After seven days following the enrollment of\n      the last patient of cohort 1, a safety assessment by the DSMC will be performed. Upon DSMC\n      approval, the second cohort of six subjects will receive a single dose of 45 mg of JVS-100\n      with a minimum of 3 days between each enrollment. After seven days following the enrollment\n      of the last patient of cohort 2, a safety assessment by the DSMC will be performed. Upon\n      DSMC approval, up to 60 subjects will be randomized (1:1:1) to receive a single dose of 30\n      mg or 45 mg of JVS-100 or matching placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to sign informed consent\n\n          -  Greater than or equal to 18 years of age\n\n          -  Poor quality of life as measured by the Minnesota Living with Heart Failure\n             Questionnaire (MLWHFQ)\n\n          -  Impaired 6 Minute Walk test\n\n          -  Ischemic cardiomyopathy without an acute coronary syndrome within the last 6 months\n\n          -  Residual well-demarcated region of LV systolic dysfunction defined as at least 3\n             consecutive segments of abnormal wall motion by echocardiography read at the\n             echocardiography core laboratory\n\n          -  LVEF less than or equal to 40% measured by echocardiography read at the\n             echocardiography core laboratory\n\n          -  Subject receiving stable optimal pharmacological therapy defined as:\n\n               -  ACE inhibitor and/or ARB, and Beta-blocker for 90 days with stable dose* for\n\n               -  30 days unless contraindicated\n\n               -  Diuretic in subjects with evidence of fluid retention\n\n               -  ASA unless contraindicated\n\n               -  Statin unless contraindicated\n\n               -  Aldosterone antagonist per physician discretion\n\n          -  Subject must not have a permanent device placed in the coronary sinus at the time of\n             enrollment *As defined as no more than 50% change in dose\n\n        Exclusion Criteria:\n\n          -  Planned revascularization within 30 days following enrollment\n\n               -  Note: if an angiographic study has been performed within the last year and the\n                  subject is enrolled, the angiography study report should be included as part of\n                  the subject's file\n\n          -  Estimated Glomerular Filtration Rate < 30 ml/min*\n\n          -  Signs of acute heart failure within 24 hours of scheduled infusion\n\n          -  History of aortic valve regurgitation classified as \"moderate-severe\" or worse\n\n          -  Patients will be excluded who have:\n\n               -  Known prior trauma to the coronary sinus\n\n               -  In dwelling instrumentation that may hamper coronary venous catheterization,\n                  including a biventricular pacing coronary sinus lead\n\n          -  Mitral regurgitation defined as \"severe\" measured by echocardiography at the clinical\n             site\n\n          -  Patients with planned mitral valve repair or replacement surgery\n\n          -  Any patient with a history of cancer will be excluded unless:\n\n               -  The cancer was limited to curable non-melanoma skin malignancies and/or\n\n               -  The cancer was removed by a successful tumor resection, with or without\n                  radiation or chemotherapy treatment, 5 years or more prior to enrollment in this\n                  study without recurrence.\n\n          -  Subjects with persistent (per ACC/AHA/EEC guidelines)53, defined as recurrent AF\n             episodes lasting longer than 7 days) or chronic atrial fibrillation will be excluded\n             unless:\n\n               -  A stable, regular heart rate is maintained with a biventricular pacemaker\n\n               -  A stable, regular heart rate is maintained with a univentricular pacemaker\n                  pacing less than or equal to 40% of the time\n\n          -  Inability to undergo 6 minute walk or treadmill exercise test\n\n          -  Previous solid organ transplant\n\n          -  Subjects with greater than 40% univentricular RV Pacing\n\n          -  Subjects with uncontrolled diabetes defined as HbA1c >10 %\n\n          -  Participation in an experimental clinical trial within 30 days prior to enrollment\n\n          -  Life expectancy of less than 1 year\n\n          -  Positive pregnancy test (serum \u03b2HCG) in women of childbearing potential and/or\n             unwillingness to use contraceptives or limit sexual activity as described in Section\n             8.2.1 below\n\n          -  Unwillingness of men capable of fathering a child to agree to use barrier\n             contraception or limit sexual activity as described in Section 8.2.1 below\n\n          -  Subjects who are breast feeding\n\n          -  Subjects with a positive test results for hepatitis B/C and/or HIV will be excluded\n             unless:\n\n               -  The subject is a carrier for hepatitis B/C but has never had an active flare\n\n          -  Subjects with a history of Systemic Lupus Erythematosus (SLE) flare\n\n          -  Total Serum Bilirubin >4.0 mg/dl\n\n          -  Aspartate aminotransferase (AST) > 120 IU/L\n\n          -  Alanine aminotransferase (ALT) > 135 IU/L\n\n          -  Alkaline phosphatase (ALP): >300 IU/L\n\n          -  Clinically significant elevations in PT or PTT relative to laboratory norms at day 0\n\n          -  Critical limb ischemia that limits the patients from completing 6 minute walk or\n             treadmill testing\n\n          -  Subjects with severe chronic obstructive pulmonary disease (COPD)\n\n               -  Severe defined as having been hospitalized for COPD within the last 12 months\n\n          -  Any subject requiring home oxygen use for treatment of the symptoms of COPD\n\n          -  History of drug or alcohol abuse within the last year\n\n          -  A subject will be excluded if he/she is unfit for the trial based on the discretion\n             of the site Principal Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01961726", 
            "org_study_id": "JTCS-003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "30 mg dose of JVS-100", 
                    "45 mg dose of JVS-100"
                ], 
                "description": "Coronary Sinus Delivery", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "45 mg dose of JVS-100"
                ], 
                "description": "Coronary Sinus Delivery", 
                "intervention_name": "30 mg dose of JVS-100", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "30 mg dose of JVS-100"
                ], 
                "description": "Coronary Sinus Delivery", 
                "intervention_name": "45 mg dose of JVS-100", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 6, 2014", 
        "location": [
            {
                "contact": {
                    "email": "sderamus@cardiologypc.com", 
                    "last_name": "Susan DeRamus", 
                    "phone": "205-780-4330", 
                    "phone_ext": "338"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35211"
                    }, 
                    "name": "Cardiology, P.C."
                }, 
                "investigator": {
                    "last_name": "Farrell O Mendelsohn, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Sarah.long@medicine.ufl.edu", 
                    "last_name": "Sarah Long", 
                    "phone": "352-273-8196"
                }, 
                "facility": {
                    "address": {
                        "city": "Gainsville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32610-0277"
                    }, 
                    "name": "University of Florida"
                }, 
                "investigator": {
                    "last_name": "David Anderson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "David White, RN", 
                    "phone": "513-585-1777"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45219"
                    }, 
                    "name": "The Carl and Edyth Lindner Center for Research & Education at The Christ Hospital"
                }, 
                "investigator": {
                    "last_name": "Eugene Chung, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Patty Meldrum", 
                    "phone": "801-585-6743"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84132"
                    }, 
                    "name": "University of Utah"
                }, 
                "investigator": {
                    "last_name": "Amit Patel, M.S., M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I/II Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Retrograde Delivery to Cohorts of Adults With Ischemic Heart Failure", 
        "other_outcome": {
            "description": "To investigate the impact of single doses of JVS-100 (either 30 or 45 mg) delivered retrograde via the coronary sinus through the Oscor Venos Occlusion Balloon catheter on quality of life measure compared to placebo at 4 months post dosing.", 
            "measure": "Impact of JVS-100 delivery on quality of life measure at 4 month follow-up", 
            "safety_issue": "No", 
            "time_frame": "4 Months"
        }, 
        "overall_contact": {
            "email": "jpastore@juventasinc.com", 
            "last_name": "Joseph Pastore, PhD", 
            "phone": "216-678-9003"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To investigate the impact of single doses of JVS-100 (either 30 or 45 mg) delivered retrograde via the coronary sinus through the Oscor Venos Occlusion Balloon catheter on 6 minute walk distance compared to placebo at 4 months post dosing.", 
            "measure": "Impact of JVS-100 delivery on 6 minute walk distance at 4 month follow-up", 
            "safety_issue": "No", 
            "time_frame": "4 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01961726"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess the impact of a single dose of JVS-100 on heart failure symptoms compared to placebo at 4 and/or 12 months post-dosing.", 
            "measure": "Impact of JVS-100 delivery on heart failure symptoms compared to placebo at 4 and/or 12 month follow-up", 
            "safety_issue": "No", 
            "time_frame": "4 and/or 12 months"
        }, 
        "source": "Juventas Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Juventas Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}